Table 4 The MLR-based comparison of baseline clinical data
Variables | Total | MLR < 0.44 | MLR ≥ 0.44 | P value |
|---|---|---|---|---|
n = 429 | n = 177 | |||
Recurrence number | 446 | 300 | 146 | 0.001 |
Early recurrence | 303 | 197 | 106 | 0.002 |
Death number | 212 | 132 | 80 | 0.001 |
Age (years old) | 56.45 ± 8.82 | 56.35 ± 8.82 | 56.69 ± 8.83 | 0.669 |
Sex (male/female) | 490/116 | 344/85 | 146/31 | 0.513 |
Hypertension (yes/no) | 147/459 | 112/317 | 35/142 | 0.098 |
Diabetes mellitus (yes/no) | 108/498 | 81/348 | 27/150 | 0.289 |
Smoking history (yes/no) | 267/339 | 189/240 | 78/99 | 0.998 |
Drinking history (yes/no) | 208/398 | 155/274 | 53/124 | 0.145 |
Antivival history (yes/no) | 301/301 | 218/207 | 83/94 | 0.325 |
Etiology (HBV/HCV/co-infection/ALD/others) | 500/58/25/15/8 | 348/44/19/12/6 | 152/14/6/3/2 | 0.722 |
Cirrhosis (yes/no) | 507/99 | 359/70 | 148/29 | 0.984 |
Child–Pugh class (A/B) | 446/160 | 316/113 | 130/47 | 0.957 |
Fractional ablation (yes/no) | 83/523 | 56/373 | 27/150 | 0.474 |
Ablative modality (RFA/MWA/AHC) | 312/157/137 | 219/103/107 | 93/54/30 | 0.060 |
Tumor number (single/multiple) | 408/198 | 296/133 | 112/65 | 0.172 |
Tumor size (≤ 30 mm/ > 30 mm) | 420/186 | 310/119 | 110/67 | 0.014 |
Alanine aminotransferase (U/L) | 39.77 ± 26.76 | 37.70 ± 25.83 | 44.80 ± 28.34 | 0.004 |
Aspartate aminotransferase (U/L) | 36.62 ± 19.66 | 36.07 ± 19.29 | 37.96 ± 20.55 | 0.283 |
Total bilirubin (μmol/L) | 19.24 ± 10.17 | 17.81 ± 9.54 | 22.70 ± 10.84 |  < 0.001 |
Albumin (g/l) | 37.03 ± 4.48 | 37.45 ± 4.54 | 35.99 ± 4.17 |  < 0.001 |
INR | 1.08 ± 0.12 | 1.07 ± 0.12 | 1.10 ± 0.12 | 0.023 |
Alpha fetoprotein (< 7/7–400/ > 400 ng/mL) | 251/299/52 | 186/204/37 | 65/95/15 | 0.319 |
Viral load (< 1000/1000–20,000/ > 20000 IU/mL) | 308/118/137 | 224/83/91 | 84/35/46 | 0.401 |
NLR | 3.23 ± 2.81 | 2.37 ± 1.78 | 5.30 ± 3.65 |  < 0.001 |
PLR | 107.59 ± 54.03 | 96.55 ± 42.45 | 134.37 ± 68.09 |  < 0.001 |